Macquarie Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.9M Buy
17,532
+4,482
+34% +$3.05M 0.05% 266
2026
Q1
$10.1M Sell
13,050
-20,767
-61% -$15.9M 0.06% 233
2025
Q4
$26.1M Sell
33,817
-52,851
-61% -$35.9M 0.11% 152
2025
Q3
$48.7M Buy
86,668
+9,943
+13% +$5.62M 0.06% 430
2025
Q2
$40.3M Sell
76,725
-2,113
-3% -$1.18M 0.05% 475
2025
Q1
$50M Sell
78,838
-175
-0.2% -$120K 0.06% 406
2024
Q4
$53.4M Buy
79,013
+3,872
+5% +$3.25M 0.06% 398
2024
Q3
$79M Sell
75,141
-1,284
-2% -$1.43M 0.09% 322
2024
Q2
$80.3M Sell
76,425
-423
-0.6% -$410K 0.09% 282
2024
Q1
$74M Sell
76,848
-1,890
-2% -$1.8M 0.08% 311
2023
Q4
$69.2M Sell
78,738
-23,013
-23% -$19M 0.08% 346
2023
Q3
$83.7M Buy
101,751
+498
+0.5% +$391K 0.11% 262
2023
Q2
$72.8M Sell
101,253
-69,846
-41% -$53.9M 0.08% 319
2023
Q1
$141M Sell
171,099
-68,587
-29% -$51.7M 0.17% 159
2022
Q4
$173M Sell
239,686
-18,887
-7% -$13.9M 0.2% 115
2022
Q3
$178M Sell
258,573
-20,339
-7% -$12.8M 0.22% 99
2022
Q2
$165M Sell
278,912
-5,396
-2% -$3.51M 0.19% 127
2022
Q1
$199M Buy
284,308
+10,575
+4% +$6.69M 0.15% 135
2021
Q4
$173M Buy
273,733
+55,802
+26% +$34.3M 0.14% 181
2021
Q3
$132M Buy
217,931
+111,854
+105% +$69.4M 0.11% 237
2021
Q2
$59.2M Buy
106,077
+2,865
+3% +$1.45M 0.05% 482
2021
Q1
$48.8M Buy
103,212
+862
+0.8% +$420K 0.07% 338
2020
Q4
$49.4M Buy
102,350
+4,164
+4% +$2.25M 0.07% 316
2020
Q3
$55M Buy
98,186
+4,356
+5% +$2.64M 0.09% 237
2020
Q2
$58.5M Buy
93,830
+10,174
+12% +$5.77M 0.1% 224
2020
Q1
$40.8M Sell
83,656
-21,574
-21% -$8.9M 0.08% 255
2019
Q4
$39.5M Sell
105,230
-191
-0.2% -$64.3K 0.06% 353
2019
Q3
$29.2M Buy
105,421
+28,000
+36% +$8.29M 0.05% 375
2019
Q2
$24.2M Buy
77,421
+10,877
+16% +$3.62M 0.04% 416
2019
Q1
$27.3M Sell
66,544
-17,816
-21% -$7.34M 0.05% 396
2018
Q4
$31.5M Buy
84,360
+14,030
+20% +$5.14M 0.06% 318
2018
Q3
$28.4M Buy
70,330
+2,790
+4% +$1.06M 0.05% 397
2018
Q2
$23.3M Buy
67,540
+5,593
+9% +$1.75M 0.04% 443
2018
Q1
$21.3M Buy
61,947
+7,823
+14% +$2.72M 0.04% 447
2017
Q4
$20.1M Buy
54,124
+27,393
+102% +$11.1M 0.04% 474
2017
Q3
$12M Sell
26,731
-4,877
-15% -$2.32M 0.02% 571
2017
Q2
$15.5M Buy
31,608
+513
+2% +$224K 0.03% 505
2017
Q1
$12.1M Sell
31,095
-7,890
-20% -$2.92M 0.02% 574
2016
Q4
$14.3M Sell
38,985
-52
-0.1% -$19.8K 0.03% 527
2016
Q3
$15.7M Buy
39,037
+3,823
+11% +$1.53M 0.03% 491
2016
Q2
$12.3M Buy
35,214
+2,514
+8% +$968K 0.02% 517
2016
Q1
$11.8M Sell
32,700
-6,250
-16% -$2.58M 0.02% 504
2015
Q4
$21.1M Sell
38,950
-1,200
-3% -$650K 0.04% 337
2015
Q3
$18.7M Buy
40,150
+4,750
+13% +$2.55M 0.04% 356
2015
Q2
$18.1M Hold
35,400
0.04% 382
2015
Q1
$16M Buy
35,400
+100
+0.3% +$42.4K 0.03% 430
2014
Q4
$14.5M Buy
35,300
+4,100
+13% +$1.61M 0.03% 443
2014
Q3
$11.2M Buy
31,200
+2,000
+7% +$670K 0.02% 480
2014
Q2
$8.25M Sell
29,200
-1,500
-5% -$445K 0.02% 554
2014
Q1
$9.22M Buy
30,700
+4,700
+18% +$1.45M 0.02% 518
2013
Q4
$7.16M Buy
26,000
+1,100
+4% +$316K 0.01% 552
2013
Q3
$7.79M Hold
24,900
0.02% 509
2013
Q2
$5.6M Buy
+24,900
New +$5.8M 0.01% 563

Other funds holding REGN

Macquarie Group's REGN Position: Q2 2026 in Review

Macquarie Group increased its Regeneron Pharmaceuticals (REGN) stake by 34% in Q2 2026, buying an estimated $3.05M and bringing the position to 17,532 shares worth $10.9M. The position accounts for 0.05% of the portfolio, ranked #266.

Macquarie Group first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $199M in Q1 2022. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Macquarie Group held 17,532 shares of Regeneron Pharmaceuticals worth $10.9M as of Q2 2026.
  • Macquarie Group bought 4,482 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.05M.
  • Regeneron Pharmaceuticals made up 0.05% of Macquarie Group's portfolio in Q2 2026, its #266 holding.
  • Macquarie Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Macquarie Group's Regeneron Pharmaceuticals position peaked at $199M in Q1 2022.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.